US Stock MarketDetailed Quotes
MXCT MaxCyte
- 4.480
- -0.170-3.66%
Close May 31 16:00 ET
- 4.470
- -0.010-0.22%
Post 17:42 ET
468.36MMarket Cap-12800P/E (TTM)
4.725High4.380Low325.26KVolume4.650Open4.650Pre Close1.47MTurnover0.36%Turnover RatioLossP/E (Static)104.54MShares5.54552wk High2.07P/B405.82MFloat Cap2.45052wk Low--Dividend TTM90.58MShs Float17.440Historical High--Div YieldTTM7.42%Amplitude2.450Historical Low4.507Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
MaxCyte Stock Forum
NEWS
MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development
MaxCyte has signed a strategic platform license agreement with Legend Biotech to accelerate the discovery and development of cell therapies. Under this non-exclusive worldwide license, Legend Biotech will use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform for various cell types, including T cells and NK cells. MaxCyte will receive an...
Larger Image: tradingview.com...
$MaxCyte(MXCT.US)$
• $Antares Pharma(ATRS.US)$ +48.7% (to be acquired by Halozyme (HALO) for $5.60 per share)
• $Sierra Oncology(SRRA.US)$ +37.9% (acquired by GSK for $55 per share)
• $Amryt Pharma(AMYT.US)$ +11.7% (announces positive long-term safety and efficacy data for Mycapssa (oral octreotide) from the 2nd Year of OPTIMAL open label extension study in acromegaly patients)
• $BriaCell Therapeutics(BCTX.US)$ +6% (presents development details of...
No comment yet